Type of security: Stock
Sector: Health Care
Industry: Medical Specialities
The data is delayed by 15 minutes.
ENZ is in the long-term down -73% below S&P in 4 years.
Description: Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 35 patient service centers in New York and New Jersey; and a standalone laboratory in the New York, as well as a full-service phlebotomy, in-house logistics department, and information technology department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug developmen
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-3.7%||Sales Growth - Q/Q||3.87%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-23.75%||ROE||-40.8%||ROI|
|Current Ratio||1.6||Quick Ratio||1.25||Long Term Debt/Equity||Debt Ratio||0.66|
|Gross Margin||43.84%||Operating Margin||-13.29%||Net Profit Margin||-14.35%||Dividend Payout Ratio|
|Cash From Financing Activities||6.37 M||Cash From Investing Activities||-1.17 M||Cash From Operating Activities||-8.17 M||Gross Profit||10.48 M|
|Net Profit||-2.91 M||Operating Profit||-2.85 M||Total Assets||58.52 M||Total Current Assets||36.06 M|
|Total Current Liabilities||22.54 M||Total Debt||3.41 M||Total Liabilities||24.46 M||Total Revenue||23.99 M|
|High 52 week||4.94||Low 52 week||2.46||Last close||3.73||Last change||1.08%|
|RSI||51.34||Average true range||0.25||Beta||1.59||Volume||42.07 K|
|Simple moving average 20 days||-0.2%||Simple moving average 50 days||0.3%||Simple moving average 200 days||10.75%|
|Performance Week||6.27%||Performance Month||2.75%||Performance Quart||0.54%||Performance Half||-6.98%|
|Performance Year||-7.44%||Performance Year-to-date||34.17%||Volatility daily||4.26%||Volatility weekly||9.51%|
|Volatility monthly||19.5%||Volatility yearly||67.55%||Relative Volume||117.6%||Average Volume||243.91 K|
|New High||New Low|
2020-03-20 06:00:00 | RPT-How one elite New York medical provider got its patients coronavirus tests
2020-03-20 01:00:00 | How one elite New York medical provider got its patients coronavirus tests
2020-03-09 14:44:16 | Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio?
2020-03-09 11:42:12 | Should You Be Concerned About Enzo Biochem, Inc.'s NYSE:ENZ ROE?
2020-03-06 18:27:06 | Edited Transcript of ENZ earnings conference call or presentation 6-Mar-20 1:30pm GMT
2020-03-06 06:30:00 | Enzo Biochem, Inc. to Host Earnings Call
2020-03-05 16:05:00 | Enzo Biochem Reports Fiscal Second Quarter Results
2020-02-25 10:27:00 | Shareholders Support the Election of Both HDF Nominees to Enzo Board of Directors
2020-02-25 09:59:00 | Enzo Biochem Announces Preliminary Results of Voting at Annual Shareholder Meeting
2020-02-19 17:16:00 | ISS Recommends Shareholders Vote AGAINST Enzo Proposal to Increase Size of Board
2020-02-07 08:00:00 | Enzo Disappointed in Harbert’s Lawsuit Aimed at Disenfranchising Shareholders
2020-01-30 08:13:00 | Enzo Comments on Harbert’s Reaction to Providing Enzo Shareholders Additional Choices
2020-01-29 10:51:00 | Harbert Discovery Fund Comments on Enzo Biochem’s Entrenchment Maneuvers
2020-01-27 06:45:00 | Harbert Discovery Fund Sends Letter to Fellow Enzo Biochem Shareholders
2020-01-17 15:02:00 | Enzo Biochem Comments on ISS Report
2020-01-08 08:49:02 | How Does Enzo Biochem, Inc. NYSE:ENZ Affect Your Portfolio Volatility?
2019-12-31 10:48:00 | Enzo Biochem Appoints Rebecca J. Fischer to Board of Directors
2019-12-30 09:00:00 | Harbert Discovery Fund Sends Letter to Fellow Enzo Biochem Shareholders
2019-12-14 19:01:58 | Is Enzo Biochem, Inc. ENZ Going To Burn These Hedge Funds ?
2019-12-10 16:15:00 | Enzo Biochem Reports Fiscal First Quarter Results
2019-12-05 16:15:00 | Enzo Biochem Issues Open Letter to Shareholders
2019-11-09 09:18:41 | What Kind Of Shareholders Own Enzo Biochem, Inc. NYSE:ENZ?
2019-10-17 20:44:48 | Edited Transcript of ENZ earnings conference call or presentation 15-Oct-19 8:30pm GMT
2019-10-15 16:15:00 | Enzo Biochem Reports Fiscal Fourth Quarter and Full Year Financial Results
2019-10-10 08:06:32 | Does Enzo Biochem, Inc.'s NYSE:ENZ CEO Salary Reflect Performance?
2019-09-24 09:00:00 | New York State Health Department Approves Hepatitis B Virus Quantitative Clinical Assay
2019-09-10 07:33:05 | Investors Who Bought Enzo Biochem NYSE:ENZ Shares Five Years Ago Are Now Down 41%
2019-08-15 07:43:03 | Is Enzo Biochem NYSE:ENZ Using Debt In A Risky Way?